Literature DB >> 15543514

Toward a new prevention of suicide in schizophrenia.

Maurizio Pompili1, Paolo Girardi, Amedeo Ruberto, Roberto Tatarelli.   

Abstract

Suicide is the primary cause of death among schizophrenic patients; follow-up studies suggested that 10-13% of schizophrenic patients die by suicide. Preventive measures based on early recognition of risk factors and the establishment of drug treatment protocols are no doubt of great help but have not resulted in a significant reduction of the number of suicides among these patients. Schizophrenia is a chronic disorder affecting all aspects of the individual's life. Prevention should therefore be addressed to various areas. This paper overviews studies dealing with major fields of interest in the prevention of suicide among patients with schizophrenia. The authors focus on the role of pharmacological treatment, psychosocial interventions and psychotherapy, the struggle against stigmatization and the role of GPs. Prevention of suicide among inpatients with schizophrenia is also analysed. It is concluded that those integrated strategies already in use and the implementation of less known interventions should constitute a more effective prevention of self-inflicted deaths among these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15543514     DOI: 10.1080/15622970410029934

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  10 in total

Review 1.  A glossary on psychiatric epidemiology.

Authors:  Huibert Burger; Jan Neeleman
Journal:  J Epidemiol Community Health       Date:  2007-03       Impact factor: 3.710

2.  Does a history of suicide attempt predict higher antipsychotic dosage in schizophrenia?

Authors:  Nuwan C Hettige; James L Kennedy; Vincenzo De Luca
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 3.  [Evidence basis of psychotherapy for schizophrenia patients in Germany].

Authors:  B Puschner; R Vauth; F Jacobi; T Becker
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

4.  Psychiatric Crisis Care and the More is Less Paradox.

Authors:  Robert E Drake; Gary R Bond
Journal:  Community Ment Health J       Date:  2021-05-15

5.  Suicide risk in schizophrenia: learning from the past to change the future.

Authors:  Maurizio Pompili; Xavier F Amador; Paolo Girardi; Jill Harkavy-Friedman; Martin Harrow; Kalman Kaplan; Michael Krausz; David Lester; Herbert Y Meltzer; Jiri Modestin; Lori P Montross; Preben Bo Mortensen; Povl Munk-Jørgensen; Jimmi Nielsen; Merete Nordentoft; Pirjo Irmeli Saarinen; Sidney Zisook; Scott T Wilson; Roberto Tatarelli
Journal:  Ann Gen Psychiatry       Date:  2007-03-16       Impact factor: 3.455

Review 6.  The Importance of Suicide Risk Formulation in Schizophrenia.

Authors:  Isabella Berardelli; Elena Rogante; Salvatore Sarubbi; Denise Erbuto; David Lester; Maurizio Pompili
Journal:  Front Psychiatry       Date:  2021-12-16       Impact factor: 4.157

7.  Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study.

Authors:  Elizabeth Scarr; Tammie Terese Money; Geoffrey Pavey; Jaclyn Neo; Brian Dean
Journal:  BMC Psychiatry       Date:  2012-08-28       Impact factor: 3.630

Review 8.  Suicidal ideation and suicidal behaviour in delusional disorder: a clinical overview.

Authors:  Alexandre González-Rodríguez; Oriol Molina-Andreu; Víctor Navarro Odriozola; Cristóbal Gastó Ferrer; Rafael Penadés; Rosa Catalán
Journal:  Psychiatry J       Date:  2014-01-30

9.  Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jordan Bertsch; David McDonnell; Holland Detke
Journal:  BMC Psychiatry       Date:  2013-09-16       Impact factor: 3.630

10.  Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia.

Authors:  Katie Beck-Felts; Marianne Goodman; Luz H Ospina; Melanie Wall; Joseph McEvoy; Lars F Jarskog; Jacob S Ballon; Matthew N Bartels; Richard Buchsbaum; Richard P Sloan; T Scott Stroup; David Kimhy
Journal:  Trials       Date:  2020-10-21       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.